Alpha-5 Integrin
About Alpha-5 Integrin
Monoclonal antibodies are developed by Alpha-5 Integrin for addressing neurological and psychiatric conditions. Proprietary formulations are targeted at diseases such as Amyotrophic Lateral Sclerosis and related disorders. Operations are conducted within the biotechnology sector, emphasizing therapeutic advancements in neurology. Focus is placed on innovative antibody-based solutions to support clinical treatments for brain health issues.
- SectorsHealthcare
- Acquired by Pasithea (Jun 2022)
Investors in Alpha-5 Integrin
Alpha-5 Integrin has secured backing from 1 investor. Prominent investors backing the company include Pasithea.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pasithea is focused on developing treatments for neurological disorders. | 2020 | pasithea.com | Miami Beach, United States |
Investor details for Alpha-5 Integrin
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Similar companies to Alpha-5 Integrin
10 companies that operate in the same segment as Alpha-5 Integrin (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Alpha-5 Integrin
Monoclonal antibodies are developed by Alpha-5 Integrin for addressing neurological and psychiatric conditions. Proprietary formulations are targeted at diseases such as Amyotrophic Lateral Sclerosis and related disorders. Operations are conducted within the biotechnology sector, emphasizing therapeutic advancements in neurology. Focus is placed on innovative antibody-based solutions to support clinical treatments for brain health issues.
Alpha-5 Integrin has 1 investor. Key investors include Pasithea.
Yes. Alpha-5 Integrin was acquired by Pasithea in June 2022.